Michael Wang, MD

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.